We present the Neuroimmunology Drug Development Summit, the industry's definitive and unrivalled forum focused on pushing the frontiers of targeting neuroinflammation for CNS Indications.
As diverse programs are advancing towards the clinic, there is a dire need to tackle the many translational challenges neuro-immunologists are facing to develop clinically effective neuroimmunology targeted therapeutics.
Building on the success of last year's meeting, this year's program will uncover how leading companies in this emerging field are discovering immune-modulating targets and deploying immuno-neurology across clinical case studies. As we gather the best minds in this infant field we will put a spotlight on the latest key learnings across microglia, astrocytes, STING, TREM2 and more to help pave the way to translating key technological and mechanistic insights towards the clinic.
Join this intimate, industry led forum to not only learn from those pioneering the field, but to network and build meaningful partnerships with 80+ neuroimmunology drug development experts.
Time: 09:00 to 17:00
Conference + 2 Workshops: USD 2997.00,
Conference + 1 Workshop: USD 2498.00,
Conference Only: USD 2299.00
Speakers: Andrea Crotti, Principal Scientist - Early Target Discovery, Takeda, Brad Friedman, Senior Scientist, Department of OMNI Bioinformatics, Genentech, Carlos Pedraza, Associate Director Neuroimmunology and MS Therapeutics, Sanofi, Charlotte Callaghan, Chief Scientific Officer and Patient Insight Manager, Ulysses Neuroscience, Christian Mirescu, Principal scientist, Neuroimmunology, Merck, Courtney Easley-Neal, Senior Scientist, In Vivo Biology and Imaging, EISAI, Graham T. Dempsey, Chief Scientific Officer, Q-State Biosciences, Juan Pablo De Rivero Vaccari, Research Assistant Professor, University of Miami Miller School of Medicine, Kristina Holmberg, Associate Director, Translational and Clinical Biomarkers, EMD Serono, M. Kerry O'Banion MD, Professor and Vice Chair, Department of Neuroscience, University of Rochester, School of Medicine and Dentistry, Maciej Kaliszczak, Senior Scientist, Biomarkers, Biogen, Marie-Eve Tremblay, Canada Research Chair in Neurobiology of Aging and Cognition, Associate Professor, Division of Medical Sciences, University of Victoria, Matthew Simon, Scientist, Denali Therapeutics, Michael Heneka, Professor, University of Bonn Medical Centre, Michelle Erickson, Research Biologist, VA Puget Sound Healthcare System ; Research assistant professor, Department of Medicine/Division of Gerontology, University of Washington, Pascal Sanchez, Director, Translational Sciences, Denali Therapeutics, Philip Ashton-Rickardt, Senior Vice President, Immunology, AZTherapies, Philip Kong, Associate Director Immuno-Neurology, Alector, Rebecca Coll, Principal Investigator, Lecturer in Immunobiology, Wellcome-Wolfson Institute for Experimental Medicine Queen's, University Belfast, UK, Robert Baloh, VP, Global Head of Research in Neuroscience and Rare Diseases, pRED at Roche, Scott Shandler, Chief Executive Officer Longevity, Biotech, Shane Liddelow, Assistant Professor, Neuroscience Institute, NYU Langone, SY Seong, Chief Executive Officer, Shaperon ; Professor, Department of Microbiology and Immunology Seoul National, University College of Medicine, William A. Banks, Associate Chief of Staff - Research and Development, VA Puget Sound ; Professor, Division of Gerontology and Geriatric Medicine, Department of Medicine, University of Washington